arrow
C

Clifton E. Barry

national institutes of health
H指数:113
被引数:5.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PET/CT imaging of tuberculosis lung lesions in marmosets treated with different drug regimens aligns with human clinical outcomes

不同药物治疗方案下卷尾猴结核肺病变的PET/CT成像结果与人类临床结局一致

2026-01-070
PRE
DIFFUSE MIDLINE GLIOMA, H3 K27 AND BRAF/FGFR1 CO-ALTERED: DISTINCT BIOLOGY AND THERAPEUTIC OPPORTUNITIES

弥漫性中线胶质瘤,H3 K27和BRAF/FGFR1共突变:独特的生物学特征和治疗机遇

2025-10-010
OAAI
The Kinetics of Bedaquiline Diffusion in Tuberculous Cavities Open a Window for the Emergence of Resistance

贝达喹啉在结核空洞中的扩散动力学为耐药性的出现提供了窗口

2025-06-010
OAAI
Identification of a Series Containing a Pentafluorophenyl Moiety That Targets Pks13 to Inhibit Growth of Mycobacterium tuberculosis

鉴定一类含有五氟苯基结构单元的化合物,该化合物靶向Pks13以抑制结核分枝杆菌的生长。

2025-02-270
OA
Distributable, metabolic PET reporting of tuberculosis
2024-06-270
OAAI
Mtb-Selective 5-Aminomethyl Oxazolidinone Prodrugs: Robust Potency and Potential Liabilities
2024-04-062
PRE
Normalizing granuloma vasculature and matrix improves drug delivery and reduces bacterial burden in tuberculosis- infected rabbits

使肉芽肿血管和基质正常化可改善药物输送并减少结核感染兔的细菌负担

2024-03-262
OAAI
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial
2024-02-166
OAAI
The Myxobacterial Antibiotic Myxovalargin: Biosynthesis, Structural Revision, Total Synthesis, and Molecular Characterization of Ribosomal Inhibition
2023-01-055
OAAI
A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study
2022-03-1517
OA